Medcura, Inc. is a commercial-stage medical device company specializing in hemostatic solutions that address surgical and traumatic bleeding. The company was founded by Dr. Matthew Dowling and is based in Riverdale, Maryland. Medcura has raised significant capital to support the development of its product line, including $22.4 million in convertible debt in 2024. The company is renowned for its biopolymer technologies and has received FDA Breakthrough Device Designations for products like LifeGel and LifeFoam.
| Attribute | Information |
|---|---|
| Founding Date | Not explicitly stated |
| Headquarters | Riverdale, Maryland, United States |
| Founders | Dr. Matthew Dowling |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Includes private equity and debt investors |
| Industry | Medical Devices, Hemostasis Solutions |
| Number of Employees | Not explicitly stated |
Medcura was founded with a clear mission to develop transformative hemostatic technologies capable of stopping bleeding rapidly in various settings, from operating rooms to battlefields. The company initially leveraged grants from the U.S. military along with private investments to build a strong foundation in the medical technology space. Early product development focused on utilizing hydrophobically modified polysaccharides as the core technology for its hemostatic products. This foundation enabled Medcura to secure multiple FDA clearances and patents, showcasing its innovative technology designed for advanced wound care.
Medcura is distinguished for its groundbreaking work in developing advanced hemostatic products designed to meet a wide array of surgical and trauma-related bleeding challenges. The company employs a unique biomaterial platform that enhances the natural adhesion properties of biopolymers. This strategic innovation has led to significant milestones:
Medcura is actively involved in enhancing its surgical hemostasis portfolio, with a focus on scalability and broad market applications. The company leverages its proprietary technology to position itself competitively within the medical device sector. Medcura's products are being developed with an eye toward reducing healthcare costs, improving safety, and enhancing outcomes in surgical and trauma settings. The company's strategic focus on innovation is instrumental in capturing a significant portion of the growing $2.5 billion global market for hemostatic technologies.
Medcura, Inc. continues to make a substantial impact in the field of medical technology with innovative solutions for hemostasis. With strategic investments and a dedicated R&D focus, Medcura is well-positioned to drive forward in its mission to provide cutting-edge bleeding management solutions. The company's proprietary technology, combined with strong leadership and market recognition, set the stage for continued influence and success in the industry.